Carvykti
The Top Pharma List rankings are compiled from GlobalData’s pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. Listed below are the charts and positions for Carvykti in this year’s pharmaceutical sales data alongside recent articles on PMLiVE featuring Carvykti.
35
2030 Global forecast Ranking
Recent articles on PMLiVE featuring Carvykti
More than 35,000 people are expected to be diagnosed with the blood cancer in the US this year
More than 35,000 new cases of the blood cancer are expected to be diagnosed in the US this year
The BCMA-targeted therapy is the first to receive approval in Europe for RRMM patients as early as first relapse
The cell therapy is the first and only BCMA-targeted therapy to be approved for this condition as early as first relapse
The blood cancer affects approximately 160,000 people worldwide
The regulator will monitor approved BCMA- or CD19-directed autologous CAR-T cell immunotherapies
An estimated 35,000 new cases of multiple myeloma will be diagnosed in the US this year
In the study, 98% of patients with relapsed or refractory multiple myeloma responded to a one-off treatment of the drug
Data provided by GlobalData
GlobalData provides trusted intelligence on the world’s largest industries including Pharmaceutical and Medical Devices. With over 2,000 in-house experts, our data-driven, technology-powered approach delivers gold-standard insights to help businesses navigate complex markets and predict future trends.
Our integrated platform empowers 4,000 of the world’s largest companies—including over 70% of FTSE 100 and 60% of Fortune 100 firms—to make timely, informed decisions through unique data, expert analysis, and innovative consulting solutions.
To find out more about how our research and insights can help you, please visit https://www.globaldata.com/who-we-are/why-globaldata/
For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE’s Top Pharma List – Methodology